Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci184043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Haipeng Tao und 38 weiteren Autor:innen. Beteiligte Einrichtung: Lillian S. Wells Department of Neurosurgery and. Hauptthemen laut MEDLINE: Receptors, Immunologic, Immune Checkpoint Inhibitors, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, U.S. Department of Defense, Oligo Nation.
Abstract (Originalsprache)
Tumor-associated macrophages (TAMs) are abundant in the tumor microenvironment (TME) and dampen the immune response, negatively affecting patient survival. Therefore, targeting TAMs could address the limitations of current cancer treatments. However, drug development in this area remains limited. The leukocyte-associated Ig-like receptor 1 (LAIR1), also called CD305, is prominently expressed on the surface of TAMs. We have uncovered what we believe to be a previously unrecognized immunosuppressive LAIR1/factor XIII A/collagen IV pathway across various cancer types. Inhibition of LAIR1, either through knockout ( Lair1 –/– ), antibody blockade (anti-Lair1 antibody), or a chimeric antigen receptor (CAR) design (3-in-1 CAR by combining tumor targeting, T cell trafficking, and remodeling of the immunosuppressive TME in 1 CAR construct) provided an enhanced antitumor response. LAIR1 inhibition enhanced peripheral and intratumoral CD8 memory T cell populations, induced a phenotypic shift of M2-like macrophages toward M1 macrophages, and normalized tumor collagen IV and structural components in the TME, facilitating effective tumor–T cell interactions and tumor suppression. Enhanced antitumor responses were observed when Lair1 –/– or anti-Lair1 antibody was used alone or in combination with CAR T cells or when the 3-in-1 CAR T cells were used solely in tumor models resistant to chemotherapy–radiation–programmed cell death protein 1 (PD-1) blockade. These findings position LAIR1 inhibition as a promising strategy for cancer immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lillian S. Wells Department of Neurosurgery and.
- The Department of Mechanical and Aerospace Engineering, University of Florida Health Cancer Center, Gainesville, Florida, USA.
- Department of Pediatrics, Division of Pediatric Hematology Oncology, and.
- Preston A. Wells, Jr. Center for Brain Tumor Therapy, University of Florida, Gainesville, Florida, USA.
- Division of Quantitative Sciences, Department of Biostatistics and.
- Bioinformatics, Interdisciplinary Center for Biotechnology Research, University of Florida Health Cancer Center, Gainesville, Florida, USA.
Förderung
- NCI NIH HHS
- U.S. Department of Defense
- Oligo Nation
- The Re-Mission Alliance Against Brain Tumors
- Rosen Foundation
- UFHCC University Scholars Program
- Florida Center for Brain Tumor Research
- Cancer Targeting and Therapeutics Research Program Pilot & Exploratory Studies (PES) RFA
Zitieren
APA
Tao, H., Chen, D., Yang, C., Nguyen, D. T., Abboud, G., Liu, R., Liu, T., Chakraborty, A., Hou, A. Y., Petit, N. A., Abbas, M., Davis, R. W., Zhang, J., Von Roemeling, C., Gbadamosi, M. O., Jin, L., Gu, T., Lin, T., Wang, P., …, & Huang, J. (2025). Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response. Journal of Clinical Investigation. https://doi.org/10.1172/jci184043
Vancouver
Tao H, Chen D, Yang C, Nguyen DT, Abboud G, Liu R, et al. Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response. Journal of Clinical Investigation. 2025. doi:10.1172/jci184043
BibTeX
@article{Tao2025,
author = {Tao, Haipeng and Chen, Dongjiang and Yang, Changlin and Nguyen, Duy T and Abboud, Georges and Liu, Ruixuan and Liu, Tianyi and Chakraborty, Avirup and Hou, Alicia Y and Petit, Nicole A and Abbas, Muhammad and Davis, Robert W and Zhang, Janie and Von Roemeling, Christina and Gbadamosi, Mohammed O and Jin, Linchun and Gu, Tongjun and Lin, Tuo and Wang, Pengchen and Pepe, Alfonso and Pedro, Diego Ivan and Mendez-Gomez, Hector R and Xie, Chao and Karachi, Aida and Weidert, Frances and Jin, Dan and Wang, Chenggang and Long-James, Kaytora and Molchan, Elizabeth K and Castillo, Paul and Ligon, John A and Ghiaseddin, Ashley P and Sayour, Elias J and Rahman, Maryam and Deleyrolle, Loic P and Kim, Betty Ys and Mitchell, Duane A and Sawyer, W Gregory and Huang, Jianping},
title = {Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci184043}
}
EUVIMED